Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia

NCT05245903 is registered in ClinicalTrials.gov with Mclean Hospital as lead sponsor.

NCT NCT05245903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress, and Cognition in Mild Cognitive Impairment and Mild Alzheimer's Dementia
Lead sponsor
Mclean Hospital
Phase
Observational
Overall status
Recruiting
Start date
May 31, 2022
Completion date
May 31, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, cognitive dysfunction, cognitive impairment, dementia, dementia alzheimers, mental disorder, mild cognitive impairment, neurocognitive disorders, neurocognitive dysfunction, neurodegenerative diseases